Skip to content

The use of erythropoietin in cardiac arrest victims: the impact on survival and neurological outcome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN67856342
Enrollment
200
Registered
2007-07-20
Start date
2007-06-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac arrest Circulatory System Cardiac arrest

Interventions

The patients in the intervention group will receive a bolus of EPO (90000 IU) in first four minutes during the CPR process. Intraosseous route is an alternative. Early application of the drug is cruci

Sponsors

Centre for Health and Emergency Medicine (Zdravstveni dom adolfa drolca maribor) (Slovenia)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 18 years or older 2. Non-traumatic, cardiac arrest in pre-hospital setting when started with cardiopulmonary reanimation irrespective of initial cardiac rhythm

Exclusion criteria

Exclusion criteria: 1. Traumatic cardiac arrest 2. Under 18 years of age 3. Cardiopulmonary Resuscitation (CPR) without drugs (only defibrillation) 4. Pregnancy 5. Severe hypothermia (<30°C)

Design outcomes

Primary

MeasureTime frame
Neurological outcome assessed by CPC, from CPC-1 (normal neorological status) to CPC-5 (brain death). This will be measured six months after cardiopulmonary resuscitation.

Secondary

MeasureTime frame
1. ROSC in the field (%) 2. ROSC with admission to hospital 3. 24-hour survival 4. Survival (discharge from hospital)

Countries

Slovenia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 3, 2026